Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not
express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth …

Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …

Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC)
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor …

Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and
progesterone receptors and the absence of HER2 overexpression. These cancers represent …

Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone
receptors expression and HER2 gene amplification and represents 24% of newly diagnosed …

Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …

Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …

Purpose: Patients with hormone receptor–negative breast cancer generally do not benefit
from endocrine-targeted therapies. However, a subset with androgen receptor (AR) …

Transcription factors are adaptor molecules that detect regulatory sequences in the DNA
and target the assembly of protein complexes that control gene expression. Yet much of the …

Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is
associated with poor long-term outcomes compared with other breast cancer subtypes …